• Sumitomo Pharma revised its fiscal 2026 forecasts on October 30.
• First-half core operating profit reached JPY 42.1 billion, exceeding the July 31 forecast of JPY 30 billion on stronger-than-expected revenue.
• Revenue rose 17.3% to JPY 266.5 billion, as U.S. growth more than offset the partial transfer of the Asian business.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Sumitomo Pharma Co. Ltd. published the original content used to generate this news brief on October 30, 2026, and is solely responsible for the information contained therein.